Compare FFBC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFBC | IBRX |
|---|---|---|
| Founded | 1863 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | N/A | N/A |
| Metric | FFBC | IBRX |
|---|---|---|
| Price | $24.93 | $2.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $28.83 | $9.71 |
| AVG Volume (30 Days) | 779.9K | ★ 13.6M |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $815,886,000.00 | $82,555,000.00 |
| Revenue This Year | $23.38 | $667.18 |
| Revenue Next Year | $19.21 | $93.03 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | 7.05 | ★ 1025.95 |
| 52 Week Low | $21.10 | $1.83 |
| 52 Week High | $29.21 | $4.27 |
| Indicator | FFBC | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 43.07 |
| Support Level | $25.94 | $1.95 |
| Resistance Level | $25.95 | $2.29 |
| Average True Range (ATR) | 0.46 | 0.12 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 13.18 | 12.73 |
First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and noninterest-bearing accounts, time deposits and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.